药品注册申请号:050475
申请类型:NDA (新药申请)
申请人:BAUSCH
申请人全名:BAUSCH HEALTH US LLC
产品信息
产品号商品名活性成分剂型/给药途径规格/剂量参比药物(RLD)生物等效参考标准(RS)治疗等效代码该申请号批准日期该产品号批准日期市场状态
001 GRIS-PEG GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Yes No AB 1975/04/16 Approved Prior to Jan 1, 1982 Prescription
002 GRIS-PEG GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Yes No AB Approved Prior to Jan 1, 1982 Prescription
批准日期,申请提交历史,通知信,药品说明书,审评文件等信息
提交状态日期提交号审批结论申请内容分类审评优先级;罕用药状态通知信、审评文件、说明书、包装标签备注
2016/04/19 SUPPL-57(补充) Approval Labeling STANDARD
2013/05/08 SUPPL-56(补充) Approval Manufacturing (CMC) STANDARD
2010/10/19 SUPPL-54(补充) Approval Labeling STANDARD
2007/01/24 SUPPL-53(补充) Approval Labeling STANDARD
2003/03/26 SUPPL-46(补充) Approval Labeling STANDARD
2002/08/01 SUPPL-51(补充) Approval Manufacturing (CMC) STANDARD
2002/06/03 SUPPL-50(补充) Approval Manufacturing (CMC) STANDARD
2001/07/02 SUPPL-49(补充) Approval Manufacturing (CMC) STANDARD
2000/12/06 SUPPL-48(补充) Approval Manufacturing (CMC) STANDARD
1998/04/16 SUPPL-47(补充) Approval Manufacturing (CMC) STANDARD
1997/04/07 SUPPL-45(补充) Approval Manufacturing (CMC) STANDARD
1988/06/20 SUPPL-8(补充) Approval Manufacturing (CMC) STANDARD
1986/09/16 SUPPL-6(补充) Approval Manufacturing (CMC) STANDARD
1985/09/16 SUPPL-5(补充) Approval Labeling
1984/10/24 SUPPL-4(补充) Approval Manufacturing (CMC) STANDARD
1984/04/24 SUPPL-3(补充) Approval Manufacturing (CMC) STANDARD
1983/02/17 SUPPL-2(补充) Approval Manufacturing (CMC) STANDARD
1983/01/26 SUPPL-1(补充) Approval Manufacturing (CMC) STANDARD
1982/12/21 SUPPL-44(补充) Approval Manufacturing (CMC) STANDARD
1982/12/21 SUPPL-43(补充) Approval Manufacturing (CMC) STANDARD
1982/06/28 SUPPL-42(补充) Approval Labeling
1982/02/05 SUPPL-41(补充) Approval Manufacturing (CMC) STANDARD
1981/07/06 SUPPL-37(补充) Approval Manufacturing (CMC) STANDARD
1981/03/05 SUPPL-34(补充) Approval Manufacturing (CMC) STANDARD
1981/03/02 SUPPL-33(补充) Approval Manufacturing (CMC) STANDARD
1980/11/21 SUPPL-31(补充) Approval Labeling
1980/11/21 SUPPL-24(补充) Approval Labeling
1980/08/13 SUPPL-32(补充) Approval Labeling
1980/01/21 SUPPL-27(补充) Approval Manufacturing (CMC) STANDARD
1980/01/04 SUPPL-29(补充) Approval Manufacturing (CMC) STANDARD
1980/01/04 SUPPL-28(补充) Approval Manufacturing (CMC) STANDARD
1979/04/10 SUPPL-25(补充) Approval Manufacturing (CMC) STANDARD
1978/01/17 SUPPL-22(补充) Approval Manufacturing (CMC) STANDARD
1977/07/26 SUPPL-21(补充) Approval Labeling
1977/04/20 SUPPL-20(补充) Approval Manufacturing (CMC) STANDARD
1976/12/08 SUPPL-19(补充) Approval Manufacturing (CMC) STANDARD
1976/11/18 SUPPL-18(补充) Approval Labeling
1976/11/18 SUPPL-17(补充) Approval Manufacturing (CMC) STANDARD
1976/10/01 SUPPL-16(补充) Approval Manufacturing (CMC) STANDARD
1976/09/16 SUPPL-13(补充) Approval Manufacturing (CMC) STANDARD
1976/08/04 SUPPL-15(补充) Approval Labeling
1976/04/01 SUPPL-12(补充) Approval Manufacturing (CMC) STANDARD
1976/01/16 SUPPL-11(补充) Approval Manufacturing (CMC) STANDARD
1975/07/16 SUPPL-9(补充) Approval Manufacturing (CMC) STANDARD
1975/06/20 SUPPL-10(补充) Approval Manufacturing (CMC) STANDARD
1975/04/16 ORIG-1(原始申请) Approval Type 5 - New Formulation or New Manufacturer STANDARD
与本品相关的专利信息(来自FDA橙皮书Orange Book)
关联产品号专利号专利过期日是否物质专利是否产品专利专利用途代码撤销请求提交日期专利下载备注
与本品相关的市场独占权保护信息
关联产品号独占权代码失效日期备注
与本品治疗等效的药品
活性成分:GRISEOFULVIN, ULTRAMICROSIZE 剂型/给药途径:TABLET;ORAL 规格:125MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050475 001 NDA GRIS-PEG GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Prescription Yes No AB Approved Prior to Jan 1, 1982 BAUSCH
061996 001 ANDA FULVICIN P/G GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Prescription No No AB Approved Prior to Jan 1, 1982 CHARTWELL RX
202545 001 ANDA GRISEOFULVIN,ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Prescription No No AB 2012/10/22 SIGMAPHARM LABS LLC
204371 001 ANDA GRISEOFULVIN, ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Prescription No No AB 2014/01/09 MOUNTAIN
202805 001 ANDA GRISEOFULVIN, ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 125MG Prescription No No AB 2018/12/26 SANDOZ
活性成分:GRISEOFULVIN, ULTRAMICROSIZE 剂型/给药途径:TABLET;ORAL 规格:250MG 治疗等效代码:AB
申请号产品号申请类型商品名活性成分剂型/给药途径规格市场状态RLDRSTE Code产品号批准日期申请人
050475 002 NDA GRIS-PEG GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Prescription Yes No AB Approved Prior to Jan 1, 1982 BAUSCH
061996 002 ANDA FULVICIN P/G GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Prescription No No AB Approved Prior to Jan 1, 1982 CHARTWELL RX
202545 002 ANDA GRISEOFULVIN,ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Prescription No No AB 2012/10/22 SIGMAPHARM LABS LLC
204371 002 ANDA GRISEOFULVIN, ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Prescription No Yes AB 2014/01/09 MOUNTAIN
202805 002 ANDA GRISEOFULVIN, ULTRAMICROSIZE GRISEOFULVIN, ULTRAMICROSIZE TABLET;ORAL 250MG Prescription No No AB 2018/12/26 SANDOZ
更多信息
药品NDC数据与药品包装、标签说明书
©2006-2024 DrugFuture->U.S. FDA Drugs Database